drugset
drugset / Trial / NCT07135219

A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy

NCT07135219 ↗

Phase 0 Enrolling by invitation 15 enrolled Peking University First Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.

Timeline

Start
2025-07-16
Primary completion
2025-12
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cizutamig Protein / enzyme biologic — Intravenous

Indications

IgA glomerulonephritis